On August 6, 2024, the U.S. Food and Drug Administration approved vorasidenib (Voranigo®), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor, for adult and pediatric patients aged 12 and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 variant, following surgery including biopsy, subtotal resection, or gross total resection.